Related Experiment Videos
Intraoperative mitomycin C in dacryocystorhinostomy
1Department of Ophthalmology, First Affiliated Hospital, Wenzhou Medical College, China.
Ophthalmic Plastic and Reconstructive Surgery
|April 3, 2001
Summary
Intraoperative mitomycin C (MMC) improves success rates in external dacryocystorhinostomy (EXT-DCR) for nasolacrimal duct obstruction. This safe adjuvant therapy enhances long-term patency and ostium size compared to standard procedures.
Area of Science:
- Ophthalmology
- Surgical Innovation
Background:
- Nasolacrimal duct obstruction (NLDO) significantly impacts quality of life.
- External dacryocystorhinostomy (EXT-DCR) is a common surgical treatment for NLDO.
- Optimizing EXT-DCR success rates remains an area of clinical interest.
Purpose of the Study:
- To evaluate the effectiveness of intraoperative mitomycin C (MMC) as an adjunct in EXT-DCR.
- To compare the long-term outcomes of EXT-DCR with and without MMC application.
Main Methods:
- A randomized controlled trial involving 46 cases (50 lacrimal drainage systems) with NLDO.
- Standard EXT-DCR in the control group.
- Application of 0.2 mg/ml or 0.5 mg/ml MMC to the osteotomy site for 5 minutes in experimental groups.
Main Results:
- All procedures were patent by irrigation at 2-3 weeks postoperatively.
- Long-term patency rates were 83% (control), 100% (0.2 mg/ml MMC), and 94% (0.5 mg/ml MMC).
- MMC groups showed significantly larger mean ostium sizes (22.2 mm² and 20.6 mm²) compared to the control (13.2 mm²), with no significant difference between MMC concentrations. No complications were reported.
Conclusions:
- Intraoperative MMC is a safe and effective adjuvant for EXT-DCR.
- MMC significantly enhances long-term success rates and ostium patency.
- This approach offers favorable outcomes for patients with nasolacrimal duct obstruction.